8F64E7A6-DEE2-426E-B843-DE4D73ECD667
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.83705650459921
- age_years
- 59
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.608
- MITOTIC_SPINDLE+0.494
- NOTCH_SIGNALING+0.491
- MYC_TARGETS_V1+0.449
- INTERFERON_ALPHA_RESPONSE+0.435
- MYC_TARGETS_V2+0.424
- PROTEIN_SECRETION+0.414
- DNA_REPAIR+0.392
- UNFOLDED_PROTEIN_RESPONSE+0.352
Top 10 suppressed
- KRAS_SIGNALING_DN-0.382
- MYOGENESIS-0.295
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.216
- XENOBIOTIC_METABOLISM-0.204
- FATTY_ACID_METABOLISM-0.203
- PANCREAS_BETA_CELLS-0.190
- SPERMATOGENESIS-0.170
- ESTROGEN_RESPONSE_LATE-0.149
- COAGULATION-0.126
- OXIDATIVE_PHOSPHORYLATION-0.125
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6A30D8D0-DDB8-4B34-8BCB-46986144F551 | — | — | 0.938 |
| 2 | SRR934774 | — | — | 0.916 |
| 3 | SRR934827 | — | — | 0.914 |
| 4 | EFB459E3-9B6A-4020-8556-6409065823B7 | — | — | 0.911 |
| 5 | SRR934861 | — | — | 0.908 |
| 6 | F226F6D3-DE88-4B15-A0F1-63EDB55E8F9D | — | — | 0.908 |
| 7 | SRR934813 | — | — | 0.907 |
| 8 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.906 |
| 9 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.903 |
| 10 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.608 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.494 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.491 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.449 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.435 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.424 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.414 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.392 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.352 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.349 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.329 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.287 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.246 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.229 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.212 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.173 | Inavolisib | — uncovered |